Julius Clinical Strengthens its European Capabilities by Expanding Operations in Poland

ZEIST, Netherlands, Feb. 25, 2025 /PRNewswire/ -- Julius Clinical, a science-driven global CRO specializing in Neurological, Cardio-Metabolic, Renal and Rare Diseases, is pleased to announce the establishment of Julius Clinical Poland, a new operational hub in Krakow. This expansion reinforces Julius Clinical's position as a global leader in CNS and Cardio-Metabolic research while enhancing its pan-European capabilities in clinical trials.

With a strong track record of over 15 clinical trials conducted in Poland during the last years, Julius Clinical recognizes the country's exceptional potential as a key clinical research hub in Europe. Poland offers a highly skilled workforce, a robust healthcare infrastructure, and a proven commitment to clinical research, making it an optimal destination for expanding the company's European footprint. The new affiliate will enable more efficient patient recruitment, improved site selection, and seamless regulatory compliance, ultimately accelerating the development of innovative therapies.

Martijn Wallert, CEO of Julius Clinical, said: "Expanding into Poland marks a strategic milestone for Julius Clinical. We are strengthening our presence in Eastern Europe, making Poland a central hub for our regional operations and expanding our ability to support clinical research across neighboring countries."

Radek Korba, Country Manager Poland, brings long-standing collaboration experience with Julius Clinical, ensuring a smooth transition for customers and partners. "Poland is a pivotal market in clinical research, and our local presence allows us to drive innovation while maintaining the highest standards of quality and compliance. We are excited to strengthen collaborations with investigators, healthcare institutions, and regulatory bodies to deliver impactful research," said Korba.

Julius Clinical's expansion into Poland aligns with its broader strategy of providing world-class, scientifically driven clinical research services globally. With this move, the company reinforces its commitment to accelerating medical breakthroughs through cutting-edge trial designs, access to diverse patient populations, and deep scientific expertise.

Julius Clinical is supported by Ampersand Capital Partners, a leading private equity firm with deep expertise in the life sciences and healthcare sectors.

About Julius Clinical

Founded in 2008 and headquartered in Zeist, The Netherlands, Julius Clinical is a leading CRO specializing in CNS, Cardio-Metabolic, Renal, and Rare Diseases. With over 380 clinical trials and 220,000+ subjects across 39 countries, Julius Clinical combines scientific leadership, operational excellence, and a global network of research sites to deliver tailored solutions for pharmaceutical, biotechnology, and academic partners.

For more information, visit https://www.juliusclinical.com or follow us on LinkedIn.

About Ampersand Capital Partners

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, The Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors.

For additional information, visit https://ampersandcapital.com or follow us on LinkedIn.

For more information on Julius Clinical services:

Email: businessdevelopment@juliusclinical.com

For more information on this press release, please contact:

Toni Kovandjieva
Marketing Manager, Julius Clinical
Email: toni.kovandjieva@juliusclinical.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/julius-clinical-strengthens-its-european-capabilities-by-expanding-operations-in-poland-302383994.html

SOURCE Julius Clinical Research